Andy Batts
Long only, value, growth, momentum

Should You Buy DexCom After The Meteoric Rise?

In my last article on DexCom (NASDAQ:DXCM) back in June last year, I argued that the stock could be a potential multi-bagger. The stock was then trading just below $22. Earlier this month, DXCM created an all-time high of $49.83 before correcting ~15%. Generally it is considered that a 15% correction from the top is a buying opportunity for a stock undergoing a secular bull phase. In this article I will analyze whether investors should consider this mild correction a buying opportunity or they should stay away from DXCM after its meteoric rise over the last twelve months.

DXCM Received FDA-Clearance for G4 PLATINUM for Pediatric Use

DXCM announced last month that it has received FDA clearance for...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details